The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ASCO GI 2021 | Phase III study of NUC-1031 for first-line treatment of CCA

Name: Phase III study of NUC-1031 for first-line treatment of CCA
Uploaded: 2021-01-07T00:00:00Z
Duration: 1 min 28 s
Description: Rachna T. Shroff, MD, University of Arizona Cancer Center, Tucson, AZ, provides an update on NuTide:121, an ongoing Phase III study of NUC-1031, a nucleoside analog, and cisplatin vs gemcitabine and cisplatin for first-line treatment of patients with advanced cholangiocarcinoma (CCA). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Rachna T. Shroff • 7 Jan 2021

ASCO GI 2021

Gastrointestinal Cancer Cisplatin Gemcitabine NUC-1031

Rachna T. Shroff, MD, University of Arizona Cancer Center, Tucson, AZ, provides an update on NuTide:121, an ongoing Phase III study of NUC-1031, a nucleoside analog, and cisplatin vs gemcitabine and cisplatin for first-line treatment of patients with advanced cholangiocarcinoma (CCA). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).